Combinations of idelalisib with rituximab and/or bendamustine in patients with recurrent indolent non-Hodgkin lymphoma

Idelalisib, a first-in-class oral inhibitor of phosphatidylinositol-3-kinase δ, has shown considerable antitumor activity as a monotherapy in recurrent indolent non-Hodgkin lymphoma (iNHL). To evaluate the safety and activity of idelalisib in combination with immunotherapy, chemotherapy, or both, 79...

Fuld beskrivelse

Na minha lista:
Bibliografiske detaljer
Udgivet i:Blood Adv
Main Authors: de Vos, Sven, Wagner-Johnston, Nina D., Coutre, Steven E., Flinn, Ian W., Schreeder, Marshall T., Fowler, Nathan H., Sharman, Jeff P., Boccia, Ralph V., Barrientos, Jacqueline C., Rai, Kanti R., Boyd, Thomas E., Furman, Richard R., Kim, Yeonhee, Godfrey, Wayne R., Leonard, John P.
Format: Artigo
Sprog:Inglês
Udgivet: American Society of Hematology 2016
Fag:
Clinical Trials and Observations
Online adgang:https://ncbi.nlm.nih.gov/pmc/articles/PMC5737161/
https://ncbi.nlm.nih.gov/pubmed/29296805
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/bloodadvances.2016000976
Tags: Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!

Lignende værker